Literature DB >> 31345548

Meta-analysis of Oxygenation Saturation Targeting Trials: Do Infant Subgroups Matter?

Lisa Maree Askie1.   

Abstract

Participant data from approximately 5000 infants have been meta-analyzed to guide oxygen saturation policy for extremely preterm infants. The Neonatal Oxygenation Prospective Meta-analysis showed that targeting a higher oxygen saturation range compared with a lower range resulted in decreased death and necrotizing enterocolitis and no difference in major disability but increased treated retinopathy of prematurity (ROP) and supplemental oxygen use at 36 weeks' postmenstrual age. The 91% to 95% range can be recommended for all extremely preterm infants from birth but should be accompanied by stringent surveillance for the prevention and early treatment of ROP.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Extremely preterm infants; Oxygen saturation targeting; Prospective meta-analysis; Subgroup analysis

Mesh:

Substances:

Year:  2019        PMID: 31345548     DOI: 10.1016/j.clp.2019.05.003

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  3 in total

1.  Incidence of Retinopathy of Prematurity in Botswana: A Prospective Observational Study.

Authors:  Alemayehu Mekonnen Gezmu; Jemal Zeberga Shifa; Graham E Quinn; Oathokwa Nkomazana; Jinyo C Ngubula; Dipesalema Joel; Francis Msume Banda; Britt Nakstad
Journal:  Clin Ophthalmol       Date:  2020-08-24

2.  Systemic Factors Associated with a Thinner Choroid in Preterm Infants.

Authors:  Suzanne M Michalak; Shwetha Mangalesh; Liangbo L Shen; Brendan McGeehan; Katrina P Winter; Neeru Sarin; Joanne Finkle; Michael Cotten; Gui-Shuang Ying; Cynthia A Toth; Lejla Vajzovic
Journal:  Ophthalmol Sci       Date:  2021-06-07

Review 3.  Supplemental Oxygen in the Newborn: Historical Perspective and Current Trends.

Authors:  Maxwell Mathias; Jill Chang; Marta Perez; Ola Saugstad
Journal:  Antioxidants (Basel)       Date:  2021-11-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.